Trichostatin A alleviates the process of breast carcinoma by downregulating LPAR5.

Y-Q Zheng, X Miao, J Li, M-F Hu, Y-S Zhu, X-R Li, Y-J Zhang

European review for medical and pharmacological sciences 2020 Jun

filter terms:

To elucidate the role of histone deacetylase inhibitor Trichostatin A (TSA) in affecting metastasis of breast carcinoma, and its molecular mechanism. LPAR5 levels in breast carcinoma tissues and paracancerous tissues were detected by quantitative real-time polymerase chain reaction (qRT-PCR), and its expression pattern was further verified in breast carcinoma cell lines. The relationship between LPAR5 and prognosis of breast carcinoma patients was analyzed. After TSA induction (100-400 nmol/L) for 6-48 h, the proliferative and migratory abilities of SKBR3 and MDA-MB-231 cells in overexpressing LPAR5 were examined by cell counting kit-8 (CCK-8), transwell and wound healing assay. By constructing a xenograft model in nude mice, the influences of TSA and LPAR5 on in vivo growth of breast carcinoma were examined. LPAR5 was upregulated in breast carcinoma samples. High level of LPAR5 predicted higher rates of lymphatic metastasis and distant metastasis, as well as lower overall survival and progression-free survival in breast carcinoma patients. LPAR5 level was dose-dependently downregulated in TSA-induced SKBR3 and MDA-MB-231 cells. In addition, TSA induction dose-dependently declined proliferative ability, and time-dependently attenuated migratory ability in breast carcinoma cells. In vivo overexpression of LPAR5 in nude mice reversed the inhibitory effect of TSA on breast carcinoma growth. TSA induction can suppress proliferative and migratory abilities in breast carcinoma by downregulating LPAR5.

Citation

Y-Q Zheng, X Miao, J Li, M-F Hu, Y-S Zhu, X-R Li, Y-J Zhang. Trichostatin A alleviates the process of breast carcinoma by downregulating LPAR5. European review for medical and pharmacological sciences. 2020 Jun;24(11):6417-6425